2690265-18-8
2690265-18-8
Chemical Structure
Etalanetug
Synonym(s): E2814
- CAS No.: 2690265-18-8
- Formula:N/A
- Molecular Weight:(146.3 kDa)
SMILES: [Etalanetug]
Biological Activity: Etalanetug (E2814) is a humanized high-affinity IgG1 antibody that targets tau protein and can cross the blood-brain barrier. Etalanetug inhibits the spread of pathological tau protein through high-affinity binding to the microtubule-binding region (MTBR). Etalanetug can be used in research related to Alzheimer's disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Etalanetug | 99.857% | Etalanetug (E2814) is a humanized high-affinity IgG1 antibody that targets tau protein and can cross the blood-brain barrier. Etalanetug inhibits the spread of pathological tau protein through high-affinity binding to the microtubule-binding region (MTBR). Etalanetug can be used in research related to Alzheimer's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Etalanetug (Mouse IgG2a) | Etalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonal antibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Rawal S,et al. An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects. Alzheimer Dis Assoc Disord. 2025 Jul-Sep 01;39(3):151-157. [Content Brief]
- [2]. Roberts M, et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020;8(1):13. Published 2020 Feb 4. [Content Brief]
Keywords
